BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Muhammad Ali, Samia Afzal, Asad Zia, Ahmed Hassan, Ali Talha Khalil, Muhammad Ovais, Zabta Khan Shinwari, Muhammad Idrees. A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challengesMedicine 2016; 95(50): e5327 doi: 10.1097/MD.0000000000005327
2
Shirin Mirza, Amna Rehana Siddiqui, Saeed Hamid, Muhammad Umar, Shaheena Bashir. Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort studyBMC Gastroenterology 2012; 12(1) doi: 10.1186/1471-230X-12-71
3
Atika Mansoor, Lubna Ali, Noor-ul Sabah, Asraf Hussain Hashmi, Mohammad Haroon Khan, Syed Ali Raza Kazmi, Nafees Ahmad, Saima Siddiqi, Khalid Mehmood Khan. Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani populationVirology Journal 2013; 10(1) doi: 10.1186/1743-422X-10-352
4
Nathan Ford, Catherine Kirby, Kasha Singh, Edward J Mills, Graham Cooke, Adeeba Kamarulzaman, Philipp duCros. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysisBulletin of the World Health Organization 2012; 90(7): 540 doi: 10.2471/BLT.11.097147
5
Muhammad Amir, Attiya Sabeen Rahman, Qaiser Jamal, Muhammad Asadullah Siddiqui. End treatment response and sustained viral response in hepatitis C virus genotype 3 among Pakistani populationAnnals of Saudi Medicine 2013; 33(6): 555 doi: 10.5144/0256-4947.2013.555
6
Sadia Ashraf, Aftab Ahmad. Viral hepatitis in Pakistan: challenges and prioritiesAsian Pacific Journal of Tropical Biomedicine 2015; 5(3): 190 doi: 10.1016/S2221-1691(15)30004-6
7
Madiha Akram, Muhammad Idrees, Shamail Zafar, Abrar Hussain, Sadia Butt, Samia Afzal, Irshad-ur Rehman, Ali Liaqat, Sana Saleem, Muhammad Ali, Azeem Butt. Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patientsVirology Journal 2011; 8(1): 234 doi: 10.1186/1743-422X-8-234
8
Ijaz S Jamall, Shafaq Yusuf, Maimoona Azhar, Selene Jamall. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?World Journal of Gastroenterology 2008; 14(43): 6627-6631 doi: 10.3748/wjg.14.6627
9
S. K. Tohra, S. Taneja, S. Ghosh, B. K. Sharma, A. Duseja, R. K. Dhiman, A. Das, Y. K. Chawla. Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis CDigestive Diseases and Sciences 2011; 56(8): 2449 doi: 10.1007/s10620-011-1770-3
10
Sadia Butt, Muhammad Idrees, Haji Akbar, Irshad ur Rehman, Zunaira Awan, Samia Afzal, Abrar Hussain, Muhammad Shahid, Sobia Manzoor, Shazia Rafique. The changing epidemiology pattern and frequency distribution of hepatitis C virus in PakistanInfection, Genetics and Evolution 2010; 10(5): 595 doi: 10.1016/j.meegid.2010.04.012
11
Alessandro Federico, Mario Masarone, Marco Romano, Marcello Dallio, Valerio Rosato, Marcello Persico. Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective StudyHepatitis Monthly 2015; 15(6) doi: 10.5812/hepatmon.15(6)2015.18640
12
Muhammad Ali, Irshad Ur Rehman, Muhammad Idrees. Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, PakistanVirus Genes 2014; 48(3): 543 doi: 10.1007/s11262-014-1047-y